ESR1 and breast carcinoma: However, besides the estrogen receptor (ER), no clinically validated options are available to support decisions to select endocrine therapy [2], despite the fact that ER + breast cancer is the most frequently occurring breast cancer subtype and endocrine therapy constitutes the largest fraction of AST administered.